These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 15918178)

  • 21. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure.
    Ferretti S; Allegrini PR; O'Reilly T; Schnell C; Stumm M; Wartmann M; Wood J; McSheehy PM
    Clin Cancer Res; 2005 Nov; 11(21):7773-84. PubMed ID: 16278399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
    Banerjee S; A'Hern R; Detre S; Littlewood-Evans AJ; Evans DB; Dowsett M; Martin LA
    Clin Cancer Res; 2010 Aug; 16(16):4178-87. PubMed ID: 20682704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model.
    Turetschek K; Preda A; Floyd E; Shames DM; Novikov V; Roberts TP; Wood JM; Fu Y; Carter WO; Brasch RC
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):448-55. PubMed ID: 12722742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.
    Goldbrunner RH; Bendszus M; Wood J; Kiderlen M; Sasaki M; Tonn JC
    Neurosurgery; 2004 Aug; 55(2):426-32; discussion 432. PubMed ID: 15271251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cluster analysis of DCE-MRI data identifies regional tracer-kinetic changes after tumor treatment with high intensity focused ultrasound.
    Jacobs I; Hectors SJ; Schabel MC; Grüll H; Strijkers GJ; Nicolay K
    NMR Biomed; 2015 Nov; 28(11):1443-54. PubMed ID: 26390040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®).
    Gaumann AK; Drexler HC; Lang SA; Stoeltzing O; Diermeier-Daucher S; Buchdunger E; Wood J; Bold G; Breier G
    Int J Oncol; 2014 Dec; 45(6):2267-77. PubMed ID: 25340839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity.
    Yamamoto A; Watanabe H; Sueki H; Nakanishi T; Yasuhara H; Iijima M
    J Dermatol; 2007 Jul; 34(7):419-29. PubMed ID: 17584317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice.
    Maier P; Unsoeld AS; Junker B; Martin G; Drevs J; Hansen LL; Agostini HT
    Graefes Arch Clin Exp Ophthalmol; 2005 Jun; 243(6):593-600. PubMed ID: 15650859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model.
    Malamas AS; Jin E; Zhang Q; Haaga J; Lu ZR
    Pharm Res; 2015 Sep; 32(9):3029-43. PubMed ID: 25840948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
    Drevs J; Medinger M; Mross K; Fuxius S; Hennig J; Buechert M; Thomas A; Unger C; Chen BL; Lebwohl D; Laurent D
    Anticancer Res; 2010 Jun; 30(6):2335-9. PubMed ID: 20651389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
    Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
    Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.
    Zwick S; Strecker R; Kiselev V; Gall P; Huppert J; Palmowski M; Lederle W; Woenne EC; Hengerer A; Taupitz M; Semmler W; Kiessling F
    J Magn Reson Imaging; 2009 May; 29(5):1125-33. PubMed ID: 19388117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis.
    Grosios K; Wood J; Esser R; Raychaudhuri A; Dawson J
    Inflamm Res; 2004 Apr; 53(4):133-42. PubMed ID: 15060719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of dynamic contrast-enhanced MRI perfusion parameters with angiogenesis and biologic aggressiveness of rectal cancer: Preliminary results.
    Yeo DM; Oh SN; Jung CK; Lee MA; Oh ST; Rha SE; Jung SE; Byun JY; Gall P; Son Y
    J Magn Reson Imaging; 2015 Feb; 41(2):474-80. PubMed ID: 24375840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of the maturity and functionality of tumor vasculature by MRI: correlation between BOLD-MRI and DCE-MRI using P792 in experimental fibrosarcoma tumors.
    Baudelet C; Cron GO; Gallez B
    Magn Reson Med; 2006 Nov; 56(5):1041-9. PubMed ID: 16986109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
    Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
    Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11.
    Kim S; Yazici YD; Barber SE; Jasser SA; Mandal M; Bekele BN; Myers JN
    Head Neck; 2006 May; 28(5):389-99. PubMed ID: 16388530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis.
    Atkin G; Taylor NJ; Daley FM; Stirling JJ; Richman P; Glynne-Jones R; d'Arcy JA; Collins DJ; Padhani AR
    Br J Surg; 2006 Aug; 93(8):992-1000. PubMed ID: 16673354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.